JP2018528786A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018528786A5 JP2018528786A5 JP2018522842A JP2018522842A JP2018528786A5 JP 2018528786 A5 JP2018528786 A5 JP 2018528786A5 JP 2018522842 A JP2018522842 A JP 2018522842A JP 2018522842 A JP2018522842 A JP 2018522842A JP 2018528786 A5 JP2018528786 A5 JP 2018528786A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- represented
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 35
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 14
- 210000002865 immune cell Anatomy 0.000 claims 14
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 102000039446 nucleic acids Human genes 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 8
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 8
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 8
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 8
- 230000003834 intracellular effect Effects 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 8
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 8
- 239000003550 marker Substances 0.000 claims 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 6
- 102000004127 Cytokines Human genes 0.000 claims 4
- 108090000695 Cytokines Proteins 0.000 claims 4
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 4
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 3
- 239000002458 cell surface marker Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 210000000581 natural killer T-cell Anatomy 0.000 claims 3
- 210000000822 natural killer cell Anatomy 0.000 claims 3
- 210000004881 tumor cell Anatomy 0.000 claims 3
- 102000009410 Chemokine receptor Human genes 0.000 claims 2
- 108050000299 Chemokine receptor Proteins 0.000 claims 2
- 102000013462 Interleukin-12 Human genes 0.000 claims 2
- 108010065805 Interleukin-12 Proteins 0.000 claims 2
- 102000003812 Interleukin-15 Human genes 0.000 claims 2
- 108090000172 Interleukin-15 Proteins 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 1
- 102000004039 Caspase-9 Human genes 0.000 claims 1
- 108090000566 Caspase-9 Proteins 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 claims 1
- 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100026720 Interferon beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 239000000611 antibody drug conjugate Substances 0.000 claims 1
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510431481.6 | 2015-07-21 | ||
| CN201510431481.6A CN106349389B (zh) | 2015-07-21 | 2015-07-21 | 肿瘤特异性抗egfr抗体及其应用 |
| PCT/CN2016/090892 WO2017012567A1 (zh) | 2015-07-21 | 2016-07-21 | 肿瘤特异性抗egfr抗体及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018528786A JP2018528786A (ja) | 2018-10-04 |
| JP2018528786A5 true JP2018528786A5 (enExample) | 2019-08-29 |
Family
ID=57833815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018522842A Ceased JP2018528786A (ja) | 2015-07-21 | 2016-07-21 | 腫瘍特異的抗ｅｇｆｒ抗体およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10927176B2 (enExample) |
| EP (1) | EP3327036B1 (enExample) |
| JP (1) | JP2018528786A (enExample) |
| KR (1) | KR20180053648A (enExample) |
| CN (1) | CN106349389B (enExample) |
| AU (1) | AU2016295601B2 (enExample) |
| CA (1) | CA2993262A1 (enExample) |
| DK (1) | DK3327036T3 (enExample) |
| ES (1) | ES2881807T3 (enExample) |
| RU (1) | RU2730605C2 (enExample) |
| SG (1) | SG11201801003YA (enExample) |
| WO (1) | WO2017012567A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106349389B (zh) * | 2015-07-21 | 2019-11-15 | 科济生物医药（上海）有限公司 | 肿瘤特异性抗egfr抗体及其应用 |
| CN105331585A (zh) | 2015-11-13 | 2016-02-17 | 科济生物医药（上海）有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| CN107326014B (zh) * | 2017-07-31 | 2019-09-24 | 时力生物科技（北京）有限公司 | 一种双特异性嵌合抗原受体修饰的t淋巴细胞及其制备方法和应用 |
| WO2019052562A1 (zh) * | 2017-09-15 | 2019-03-21 | 科济生物医药（上海）有限公司 | Il-4r的融合蛋白及其应用 |
| CN109796532B (zh) * | 2017-11-17 | 2024-09-10 | 恺兴生命科技(上海)有限公司 | 靶向成纤维激活蛋白α的结合单元及其应用 |
| CN109836497A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种靶向egfr的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| CA3116314A1 (en) * | 2018-10-15 | 2020-04-23 | Board Of Regents, The University Of Texas System | Monoclonal antibodies against human dickkopf3 and uses thereof |
| EP3892333A4 (en) * | 2018-12-07 | 2022-11-30 | CRAGE medical Co., Limited | Tumor combined immunotherapy |
| EP3954762A4 (en) | 2019-03-28 | 2023-01-18 | Korea Research Institute of Bioscience and Biotechnology | METHOD FOR PRODUCTION OF NK CELLS WITH A CAR GENE INTRODUCED THEREOF, AND USE THEREOF |
| CN109929039A (zh) * | 2019-03-28 | 2019-06-25 | 郑州大学第一附属医院 | 基于cd276抗体的嵌合抗原受体、慢病毒表达载体及其应用 |
| CN114729328B (zh) * | 2019-11-13 | 2024-05-03 | 上海医药集团股份有限公司 | Tmem59蛋白二聚体或嵌合表达受体改善t细胞功能 |
| WO2021102131A1 (en) * | 2019-11-21 | 2021-05-27 | Brown University | Bispecific antibodies against chi3l1 and ctla4 with enhanced cytotoxic effects on tumor cells |
| CN111534532A (zh) * | 2020-03-30 | 2020-08-14 | 华东理工大学 | 噬菌体药物蛋白展示系统及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA952174B (en) * | 1994-03-17 | 1995-12-27 | Merck Patent Gmbh | Anti-EGFR single-chain fvs and anti-EGFR antibodies |
| IL128852A0 (en) * | 1999-03-05 | 2000-01-31 | Compugen Ltd | Novel nucleic acid and amino acid sequences |
| US20100056762A1 (en) * | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| AU2002314491A1 (en) * | 2001-06-20 | 2003-01-02 | Compugen Ltd. | Nucleic acid and amino acid sequences of a vegf variant |
| US7736644B2 (en) * | 2003-06-27 | 2010-06-15 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| EP2091975A4 (en) * | 2006-11-21 | 2013-05-22 | Univ California | ANTIBODIES TO THE EGFR FAMILY, BICE-SPECIFIC ANTIBODIES TO THE EGFR FAMILY AND METHOD FOR THEIR USE |
| EP2436397B1 (en) * | 2009-05-29 | 2017-05-10 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition containing antagonist of egf family ligand as component |
| CN103382223B (zh) * | 2012-04-01 | 2015-06-10 | 上海益杰生物技术有限公司 | 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽 |
| CN103113470B (zh) * | 2013-02-27 | 2015-04-22 | 四川大学 | 靶向人egfr的基因工程化淋巴细胞及其制备方法和用途 |
| CN104087607B (zh) | 2013-04-01 | 2017-06-20 | 科济生物医药（上海）有限公司 | 编码嵌合抗原受体蛋白的核酸及表达嵌合抗原受体蛋白的t淋巴细胞 |
| CN106349389B (zh) * | 2015-07-21 | 2019-11-15 | 科济生物医药（上海）有限公司 | 肿瘤特异性抗egfr抗体及其应用 |
| CN108884459B (zh) * | 2016-04-26 | 2024-04-02 | 科济生物医药（上海）有限公司 | 一种改善免疫应答细胞功能的方法 |
-
2015
- 2015-07-21 CN CN201510431481.6A patent/CN106349389B/zh active Active
-
2016
- 2016-07-21 SG SG11201801003YA patent/SG11201801003YA/en unknown
- 2016-07-21 AU AU2016295601A patent/AU2016295601B2/en not_active Expired - Fee Related
- 2016-07-21 WO PCT/CN2016/090892 patent/WO2017012567A1/zh not_active Ceased
- 2016-07-21 DK DK16827258.1T patent/DK3327036T3/da active
- 2016-07-21 EP EP16827258.1A patent/EP3327036B1/en active Active
- 2016-07-21 JP JP2018522842A patent/JP2018528786A/ja not_active Ceased
- 2016-07-21 KR KR1020187005181A patent/KR20180053648A/ko not_active Ceased
- 2016-07-21 RU RU2018104703A patent/RU2730605C2/ru active
- 2016-07-21 US US15/746,711 patent/US10927176B2/en active Active
- 2016-07-21 CA CA2993262A patent/CA2993262A1/en not_active Abandoned
- 2016-07-21 ES ES16827258T patent/ES2881807T3/es active Active
-
2021
- 2021-02-23 US US17/182,956 patent/US20220017625A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018528786A5 (enExample) | ||
| JP2018522564A5 (enExample) | ||
| AU2020270507B2 (en) | Chimeric antigen receptors, compositions, and methods | |
| JP2018529327A5 (enExample) | ||
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| CN108884164B (zh) | 用于免疫疗法的经修饰细胞 | |
| CN107880128B (zh) | 一种抗cd19的全人源抗体或抗体片段及其方法和应用 | |
| RU2018105963A (ru) | Антитело против глипикана-3 и его применение | |
| CN112912401B (zh) | 抗-l1细胞粘附分子抗体或其抗原结合片段及包含其的嵌合抗原受体 | |
| JP2020500010A (ja) | 分泌性バリアント免疫調節タンパク質および改変細胞療法 | |
| JP2019525771A5 (enExample) | ||
| JP2018526033A5 (enExample) | ||
| JP7064663B2 (ja) | Ｉｌ－１３ｒａ２を標的とする抗体及びその応用 | |
| JPWO2017020812A5 (enExample) | ||
| KR20220104204A (ko) | Prame tcr 수용체 및 이의 용도 | |
| JP2020532280A (ja) | 細胞により発現される生物学的活性を調節する結合分子 | |
| WO2017064084A1 (en) | Novel chimeric antigen receptors | |
| JP2021528382A (ja) | 免疫エフェクター細胞を腫瘍細胞へ誘引する方法及び手段 | |
| CN115403671A (zh) | 靶向Claudin18.2的纳米抗体及其用途 | |
| CN104829725A (zh) | 一种双特异性抗体cd133×cd3的构建及应用 | |
| Pfeifer Serrahima et al. | Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2-positive malignancies | |
| KR20230042090A (ko) | 항-cd22 단일 도메인 항체 및 치료학적 작제물 | |
| JPWO2020219843A5 (enExample) | ||
| JPWO2022235662A5 (enExample) |